linjc16/ctgov huggingface dataset:
Influence of Spinal Deformity on THA

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to understand the effect of spinal deformity and altered sagittal plane parameters of lumbosacral complex on acetabular cup position in THA.

Detailed Description
-----------------
Investigators will Find out if there is change in the acetabular cup including the abduction and anteversion angles in patients who had THA and has spinal deformity

Official Title
-----------------
Influence of Spinal Deformity on Acetabular Cup Position in THA.

Conditions
-----------------
THA

Intervention / Treatment
-----------------
* Procedure: THA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients who had primary THA in 6 month duration patients from 30 to 70 years old with primary THA Exclusion Criteria: patients who have ankylosing spondylitis patients with revised THA patients with associated injuries in lower limb

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: THA|positioning the acetabular cup regarding abduction and anteversion angles with or without concern to spinal deformity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of acetabular cup position in spinal deformity | change of acetabular cup abduction and anteversion angles in patients who has THA and spinal deformity | immediate post operative X-ray hip anteroposterior and cross table lateral views in supine position measuring cup abduction and anteversion angles and 3 month post operative X-ray hip and lumbosacral anteroposterior and lateral views in standing position | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complications of THA mainly hip dislocation and HOOS hip survey | post-operative hip dislocation | 3 month duration post operatively |
Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

Study Overview
=================
Brief Summary
-----------------
First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC). While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative. In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Official Title
-----------------
Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

Conditions
-----------------
Autoimmune Encephalitis

Intervention / Treatment
-----------------
* Other: Long-term outcome


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022. Exclusion Criteria: tested positive to another onconeural antibody.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anti-GABABr encephalitis<br>This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments. | Other: Long-term outcome<br>* Autonomy, physical examination, behavioural disorders<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified-Rankin scale (mRS) | Modified-Rankin scale (mRS) ranked from 0 (full autonomy) to 6 (death) | At 60 month (after the beginning of the disease) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anti-GABAbr, autoimmune encephalitis, outcome
Sentinel Lymph Nodes Biopsy in Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
This study aims to compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage cervical cancer who underwent radical hysterectomy.

Official Title
-----------------
Sentinel Lymph Nodes Biopsy Versus Lymphadenectomy in Cervical Cancer

Conditions
-----------------
Sentinel Lymph Node

Intervention / Treatment
-----------------
* Procedure: sentinel lymph node biopsy
* Procedure: comprehensive pelvic lymphadenectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 20 and above with clinical FIGO stage I-IIA cervical cancer Exclusion Criteria: Women did not receive surgical treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sentinel Lymph Node<br>Sentinel lymph node biopsy in patients with early stage cervical cancer | Procedure: sentinel lymph node biopsy<br>* sentinel lymph node biopsy<br>|
| Lymphadenectomy<br>Comprehensive lymphadenectomy in patients with early stage cervical cancer | Procedure: comprehensive pelvic lymphadenectomy<br>* comprehensive pelvic lymphadenectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression free survival | progression free survival between these two groups | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival | overall survival between these two groups | 5 years | 
| Number of dissected lymph node | Number of dissected lymph node between these two groups | 5 years |
Sex-related Differences in Outcome After Hybrid Coronary Revascularization

Study Overview
=================
Brief Summary
-----------------
Hybrid coronary revascularization (HCR) has emerged as a favorable technique over traditional coronary artery bypass grafting (CABG) in a select group of patients with multivessel coronary artery disease (CAD). Till date, multiple individual studies comparing HCR with CABG have been carried out, but no data on the potential impact of sex on the outcome of HCR exist. To fill this knowledge gap, the investigators aim to perform an international collaborative multi-center study in order to examine gender differences in short-term and long-term outcomes among patients who underwent HCR or CABG.

Detailed Description
-----------------
Hybrid coronary revascularization (HCR) has emerged as a favorable technique over traditional coronary artery bypass grafting (CABG) in a select group of patients with multivessel coronary artery disease (CAD). Till date, multiple individual studies comparing HCR with CABG have been carried out, but no data on the potential impact of sex on the outcome of HCR exist. Limited by their sample size, these individual studies may have been under-powered to detect a difference. To fill this knowledge gap, the investigators aim to perform an international collaborative multi-center study in order to examine gender differences in short-term and long-term outcomes among patients who underwent HCR or CABG.

Official Title
-----------------
Sex-related Differences in Outcome After Hybrid Coronary Revascularization Versus Coronary Artery Bypass Grafting in Multivessel Coronary Artery Disease: The SEX-HYBRID Study

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: HYBRID


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with coronary artery disease and indication to cardiac surgery Exclusion Criteria: Contraindications to cardiac surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: HYBRID|It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Overall Mortality | All causes deaths | Up to 1 year | 
| Incidence of Composite End-point | Cardiac death, myocardial infarction, stroke, bleeding | Up to 1 year |
Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal

Study Overview
=================
Brief Summary
-----------------
This is a observational study conducted at the department of Ear ,Nose and Throat -Head and Neck Surgery (ENT-HNS) of Shree Birendra Hospital ,a tertiary health care centre of Nepal. Head and Neck cancers are the sixth most common cancer in the world. Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023.The main aim of the study was to know about the common cancers of head and neck region and their distribution according to the site. Also to know the stage of the presentation with treatment modalities in the tertiary health care centre of Nepal.

Detailed Description
-----------------
This is a retrospective study to know the prevalence of Head and Neck Cancer at the department of ENT- Head and Neck Surgery of Shree Birendra Hospital ,a tertiary health care centre of Nepal .Head and neck cancers are malignant neoplasms that develops in oral cavity, nasal cavities, paranasal sinuses,nasopharynx, oropharynx, hypopharynx, ear, scalp, salivary gland and neck,Data was collected from the medical records of Head and Neck Cancer patients who underwent treatment between May 2022 to April 2023. Data considered of demographic details of age, sex, diagnosis, subsite specific Head and Neck Cancers, treatment modality and histopathology. The data was analyzed using Stastical Package for Social Sciences (SPSS) version 22. Pearson's chi-square test was applied and p value <0.05 was considered statistically significant.

Official Title
-----------------
Clinicopathological Profile of Head and Neck Cancers in Army Hospital of Nepal - A Retrospective Study

Conditions
-----------------
Head and Neck Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All histologically proven cases of head and neck region. Exclusion Criteria: Patient's record with incomplete data.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Age - wise Distribution of Head and Neck Cancers (HNCs) | Age - wise Distribution of Head and Neck Cancer | 1 year | 
| : Distribution of HNCs according to subsite | Distribution of Head and Neck Cancers according to the subsite | 1 year | 
| Histopathology of HNCs | Histopathology of Head and Neck Cancer | 1 year | 
| Tumor, Nodes, Metastasis (TNM) staging of HNC | Staging at presentation of Head and Neck Cancer | 1 year | 
| Treatment provided to HNC patients | Treatment Modalities of Head and Neck Cancer | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Head and Neck Cancer, Radiotherapy, Chemotherapy
Comparing Preschool-Aged Refractive Measurements and Amblyopia Risks Using the 2WIN-S Portable Refractor With Vision Screening by Cycloplegic Refraction in Bangkok

Study Overview
=================
Brief Summary
-----------------
The goal of this diagnostic test is to compare the results of refraction and amblyopia risks between using 2WIN-S portable refractor and cycloplegic refraction in pre-school age. All participants will be tested by 2WIN-S portable refractor.

Official Title
-----------------
Comparing Preschool-Aged Refractive Measurements and Amblyopia Risks Using the 2WIN-S Portable Refractor With Vision Screening by Cycloplegic Refraction in Bangkok

Conditions
-----------------
2WIN-S Portable Refractor

Intervention / Treatment
-----------------
* Diagnostic Test: 2WIN-S portable refractor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: corrected visual acuity 0.1 logMAR (Snellen 20/25) or better Age 3-6 years old who studies in the kindergarten school that joins the study Parents sign informed consent form about allowing their child to join the study Exclusion Criteria: other eye conditions causing visual and 2WIN-S portable refractor working disturbance such as media opacity, history of ocular surgery, strabismus, etc.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Using 2WIN-S portable refractor for amblyopia screening<br> | Diagnostic Test: 2WIN-S portable refractor<br>* All participants will be tested by 2WIN-S portable refractor without eye dilatation. If the 2WIN-S reports non-referral, participant will be tested visual acuity by optometrist. If the 2WIN-S reports referral, participant will be tested cycloplegic refraction by pediatric ophthalmologist, then tested by 2WIN-S again. The participant whose result is abnormal will be referred to the hospital for further management.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Significant refractive errors defined by AAPOS | Measuring spherical equivalent(SE) and cylinder(Cy), and axis to detect specific target levels of ARFs and visually significant refractive errors, as defined by AAPOS. | At baseline. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy for Amblyopia | Diagnostic accuracy for Amblyopia, measuring by 2WIN-S device and pediatric ophthalmologist. | At baseline. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Refraction, vision screening, preschool aged children
A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women

Study Overview
=================
Brief Summary
-----------------
INSIGHT is a Prospective, Observational, open-label cohort study on women in Sub-Saharan Africa on PrEP screening, informed choice, and compliance. There are no specific intervention arms or comparative treatment plans. We will follow and observe participants taking PrEP, not taking PrEP, as well as those who begin or end PrEP during the course of the observational period.

Detailed Description
-----------------
Primary goals: Estimate HIV incidence using recency testing on samples from women who screen out due to HIV infection, as well as assess HIV incidence prospectively in the cohort. Assess the characteristics of women who initiate PrEP compared to those who do not initiate PrEP. Evaluate young women's preferences for attributes of long-acting formulations of PrEP, using a discrete choice experiment. Assess the acceptability of a patient-facing PrEP decision support tool to provide young women more informed choice about PrEP options.

Official Title
-----------------
A Cohort for Evaluation of Open-label PrEP Delivery and PrEP Preferences Among African Women

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: PrEP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 16-30 years of age Female Exclusion Criteria: not sexually active over 31 years of age at consent

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 31 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: PrEP|Eligible women will be prescribed PrEP intake in accordance to standard of care should they choose. We are interested in observing adherence, barriers to adherence, and other factors that effect sexual health.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A cohort for evaluation of open-label PrEP delivery and PrEP preferences among African women | We will collect data on STI prevalence, contraception use, sexual behavior, risk perception as correlates for PrEP uptake, persistence and adherence. Adherence will be measured by the timing of PrEP refills, self-reported PrEP use, and drug level testing for tenofovir (TFV) levels .PrEP adherence will be assessed during periods of risk, based on behavioral data and self-perceived risk. Participants in this cohort will be informed of other HIV prevention efficacy trials. A discrete choice experiment will be used to assess women's preferences around PrEP delivery form (pill and injection), dosing frequency, and relative dose forgiveness for different PrEP formulations. A patient-facing decision support tool about PrEP options will be evaluated with respect to its utility in assisting young women to consider their HIV prevention needs and PrEP preferences. | 1 year |
prehospItal maNagement oF paroxysmaL supraventrICular Tachycardia

Study Overview
=================
Brief Summary
-----------------
Retrospective multicentre study on management of supraventricular tachycardia in prehospital setting.

Detailed Description
-----------------
Supraventricular tachycardia in prehospital setting may be managed with adenosine administration or with synchronised electrical cardioversion and there's no clear advantage between the two, even if international guidelines suggests to practice drug-first method.This study aims to evaluate any difference in outcomes and efficacy of the two methods and possible adverse effects of both.

Official Title
-----------------
prehospItal maNagement oF paroxysmaL supraventrICular Tachycardia - Gestione Preospedaliera Della Tachicardia Parossistica Sopraventricolare

Conditions
-----------------
Tachycardia, Supraventricular

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients accepting to participate patients affected by supraventricular tachycardia that are managed prehospitally by the emergency medical service Exclusion Criteria: not willing to participate, not able to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| supraventricular tachycardia treated with intra-venous adenosine<br>supraventricular tachycardia treated with intra-venous adenosine | |
| supraventricular tachycardia treated with electrical synchronised cardioversion<br>supraventricular tachycardia treated with electrical synchronised cardioversion | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of adenosine versus electric cardioversion in obtaining successful cardioversion of PSVT | absolute numbers and relative percentages of successful prehospital cardioversions obtained with the two techniques | Prehospital EMS assistance time | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic accuracy for supraventricular tachycardia of the emergency medical service personnel | Sensitivity for PSVT of the EMS personnel | Prehospital EMS assistance time | 
| adverse events | incidence of predefined serious adverse events (SAE) between the two groups | Prehospital EMS assistance time | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
supraventricular tachycardia